COYA 302 Heads to Phase 2 Trial of ALS Following IND Acceptance
The FDA has accepted the IND for COYA 302, a Treg-targeting combination therapy for ALS, clearing the way for a pivotal phase 2 multicenter trial.
Previous Post
Andrea Swift: Taylor Swift’s Mom Knee Surgery Costs Vary From $12K to $197K
Next Post
Fostering Collaboration Among Nurses for Optimal Health Outcomes in Oklahoma
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago